Chiesi Farmaceutici Spa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Chiesi Farmaceutici Spa (US): 6 reconciled FDA prescription therapies, $100.6M 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies6
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2039-01-01
2024 CMS Total Public Spend$100.6M
2024 Medicare Part D Spend$37.1M
2024 Medicaid Spend$63.5M
California HCAI SB 17 Filings11 WAC filings (max 16.3% 2-yr change)